ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,746Medicare Part D Prescriptions Filled, Including Refills

Rank: 192 out of 2456

$440K Total Retail Price of All Prescriptions

Rank: 290 out of 2456

508 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 508 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

10% of this provider’s 508 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 7,150 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
LISINOPRIL 590 497 1 1
SIMVASTATIN 406 317 2 2
LEVOTHYROXINE SODIUM 389 334 3 4
ATENOLOL 317 285 4 6
FUROSEMIDE 271 219 5 8
WARFARIN SODIUM 231 209 6 9
HYDROCODONE-ACETAMINOPHEN 208 79 S3 7 20
AMLODIPINE BESYLATE 207 169 8 5
HYDROCHLOROTHIAZIDE 204 192 9 7
METOPROLOL TARTRATE 193 152 10 10
ATORVASTATIN CALCIUM 188 153 11 12
METFORMIN HCL 182 150 12 11
PRAVASTATIN SODIUM 160 117 13 15
OMEPRAZOLE 151 69 14 3
GABAPENTIN 137 100 15 16
PROAIR HFA 128 89 16 22
LORAZEPAM 124 120 17 67
ALLOPURINOL 117 104 18 27
GLYBURIDE 111 98 R 19 40
MORPHINE SULFATE ER 110 17 S2 20 98
ADVAIR DISKUS 110 58 20 36
LOSARTAN POTASSIUM 107 105 22 18
IBUPROFEN 91 21 23 52
TRAZODONE HCL 90 23 24 17
GEMFIBROZIL 86 76 25 93
SERTRALINE HCL 81 35 26 21
ALENDRONATE SODIUM 78 78 27 19
DEXILANT 78 58 27 114
OXYCODONE-ACETAMINOPHEN 77 54 S2 29 35
FLUOXETINE HCL 74 35 30 45
CITALOPRAM HBR 74 40 30 14
CLONAZEPAM 71 35 32 280
FLUTICASONE PROPIONATE 70 50 33 30
KLOR-CON M20 69 69 34 69
INSULIN SYRINGE 67 54 35 72
RANITIDINE HCL 66 55 36 31
LISINOPRIL-HYDROCHLOROTHIAZIDE 61 61 37 41
DIGOXIN 60 56 38 49
OXYCODONE HCL-ACETAMINOPHEN 59 0 S2 39 101
NIFEDIAC CC 59 59 39 175
ZOLPIDEM TARTRATE 57 39 41 28
CYCLOBENZAPRINE HCL 55 0 R 42 77
LOVASTATIN 53 49 43 34
KLOR-CON M10 52 38 44 196
METOPROLOL SUCCINATE 52 48 44 13
DIOVAN 51 32 46 26
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 1, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.